Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
B176153-50mg | 50mg | In stock | $355.90 | |
B176153-250mg | 250mg | In stock | $1,602.90 | |
B176153-1g | 1g | In stock | $5,767.90 |
Synonyms | Betrixaban|330942-05-7|PRT054021|Bevyxxa|N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide|PRT 054021|PRT-054021|UNII-74RWP7W0J9|Betrixaban [USAN]|74RWP7W0J9|N-(5-Chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)be |
---|---|
Specifications & Purity | Moligand™, ≥97% |
Biochemical and Physiological Mechanisms | Betrixaban is an orally active, active site-targeting, highly potent and selective factor Xa (fXa) inhibitor (IC50 = 1.5 nM; Ki = 117 pM) with much reduced plasma kallikrein inhibitory activity (IC50 = 6.3 μM) and little potency against thrombin, trypsin, |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Coagulation factor X inhibitor |
Product Description | Product Description: Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with IC50 of 1.5 nM |
ALogP | 3.6 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide |
---|---|
INCHI | InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31) |
InChi Key | XHOLNRLADUSQLD-UHFFFAOYSA-N |
Canonical SMILES | CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl |
Isomeric SMILES | CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl |
PubChem CID | 10275777 |
Molecular Weight | 451.91 |
ChEMBL Ligand | CHEMBL512351 |
---|---|
PubChem CID | 10275777 |
BindingDB Ligand | 50249298 |
CAS Registry No. | 330942-05-7 |
Reactome Reaction | R-HSA-9015122, R-HSA-9015111 |
Reactome Drug | R-ALL-9038746 |
DrugCentral Ligand | 5241 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
A2305119 | Certificate of Analysis | Aug 31, 2022 | B176153 |
A2305142 | Certificate of Analysis | Aug 31, 2022 | B176153 |
L2210342 | Certificate of Analysis | Aug 31, 2022 | B176153 |
L2210355 | Certificate of Analysis | Aug 31, 2022 | B176153 |
L2210358 | Certificate of Analysis | Aug 31, 2022 | B176153 |
Pictogram(s) | GHS08, GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H373:Causes damage to organs through prolonged or repeated exposure H302:Harmful if swallowed |
Precautionary Statements | P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P260:Do not breathe dust/fume/gas/mist/vapors/spray. P270:Do not eat, drink or smoke when using this product. P330:Rinse mouth. P301+P317:IF SWALLOWED: Get medical help. P319:Get medical help if you feel unwell. |
1. Zhang P, Huang W, Wang L, Bao L, Jia ZJ, Bauer SM, Goldman EA, Probst GD, Song Y, Su T et al.. (2009) Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.. Bioorg Med Chem Lett, 19 (8): (2179-85). [PMID:19297154] |